Daiichi Sankyo Lifts Sales Outlook on Cancer Drugs, Trims Profit Forecast on Tax Bill
Enhertu and Datroway drove a 21.1% revenue jump for Daiichi Sankyo and prompted an upgraded sales and operating-profit outlook, yet a jump in the effective tax rate to 24.9% means the company actually cut its full-year net profit guidance by ¥9bn.